马上注册,结交更多好友,下载更多分子模拟资源。
您需要 登录 才可以下载或查看,没有帐号?我想注册
x
本帖最后由 dejunchem 于 2013-6-19 19:38 编辑
Abstract Pharmaceutical innovation is often measured by counting the new drugs approved by regulators. It is a simple and useful metric, but it has shortcomings. One of them is that it says little about the drugs’ innovativeness. Are they variations of older medicines, or molecules targeting entirely novel modes of action? As prices escalate, and payers and patients demand value, we need a better picture. This paper tries to provide it by analyzing the drugs approved by the U.S. FDA between 2000 and 2012. It examines their modes of action, highlights key trends and discusses their implications for our ability to generate innovation.
|